FdaApplication
NDA 217785
Identifiers
- fda_app_no: NDA217785
Properties
| Property | Value |
|---|---|
| applicant_name | MADRIGAL PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2024-03-14 |
Revenue by product
REZDIFFRA
| Period | Revenue |
|---|---|
| Q2 2026 | $364.3M† |
| Q1 2026 | $311.3M† |
| Q4 2025 | $321.1M† |
| Q3 2025 | $287.3M† |
| Q2 2025 | $212.8M† |
| Q1 2025 | $137.3M† |
| Q4 2024 | $103.3M† |
| Q3 2024 | $62.2M† |
| Q2 2024 | $14.6M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $0.0M† |
| Q3 2023 | $0.0M† |
| Q2 2023 | $0.0M† |
| Q1 2023 | $0.0M† |
| Q4 2022 | $0.0M† |
| Q3 2022 | $0.0M† |
| Q2 2022 | $0.0M† |
| Q1 2022 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REZDIFFRA | RESMETIROM | 100MG | TABLET;ORAL |
| REZDIFFRA | RESMETIROM | 60MG | TABLET;ORAL |
| REZDIFFRA | RESMETIROM | 80MG | TABLET;ORAL |
3 products